Response to: Letter to Editor Regarding "Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study"
Dermatol Ther (Heidelb)
.
2024 Apr;14(4):1067-1069.
doi: 10.1007/s13555-024-01138-8.
Epub 2024 Apr 5.
Author
A David Burden
1
Affiliation
1
School of Infection and Immunity, University of Glasgow, Glasgow, UK. david.burden@glasgow.ac.uk.
PMID:
38578385
PMCID:
PMC11052932
DOI:
10.1007/s13555-024-01138-8
No abstract available
Publication types
Letter